A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)

A Phase III Open-Label Study of Immunogenicity, Safety, and Tolerability of 2 Doses of VAQTA™ (Formalin, Inactivated, Alum-Adjuvanted Hepatitis A Vaccine) in Healthy Children 12 to 23 Months of Age

This study will demonstrate the immunogenicity and evaluate the safety/tolerability of the vaccine in Chinese children between 12 and 23 months of age.

Inclusion Criteria:

• Healthy Chinese children 12 to 17 months old at receipt of the first study vaccination

Exclusion Criteria:

• Subject is Hepatitis A virus antibody positive at screening or has a history of Hepatitis A infection
• Subject has a fever 72 hours prior to first injection
• Subject has already been vaccinated for Hepatitis A
• Subject is allergic to aluminum, formaldehyde, sodium borate, latex, or any component of the vaccine
• Subject has received inactivated vaccines within 14 days of screening or live vaccines within 30 days of screening